Background
Methods
Data collection
Data analysis
Ethics, consent and permissions
Results
Enrolment
Total—n | 617 |
---|---|
Registered within KHDSS—n (%) | 566 (92) |
Route of HIV testing—n (%) | |
CRH | 275 (45) |
HIV serosurvey | 277 (45) |
Missing | 65 (11) |
Sex—n (%) | |
Male | 248 (40) |
Female | 369 (60) |
Age—n (%) | |
15–34 | 257 (42) |
≥35 | 360 (58) |
Median age—years | 37.0 |
Weight—kg | |
Median (IQR) | 52.6 (47.8–59.0) |
Median BMI | 20.2 |
Year—n (%) | |
2008 | 227 (37) |
2009 | 175 (28) |
2010 | 148 (24) |
2011 | 67 (11) |
WHO stage—n (%) | |
I | 122 (20) |
II | 251 (41) |
III | 196 (32) |
IV | 48 (8) |
CD4 count—n (%) | |
≤250 cells/μL | 315 (51) |
251–350 cells/μL | 93 (15) |
351–500 cells/μL | 85 (14) |
>500 cells/μL | 109 (18) |
Missing | 15 (2) |
Median CD4 count—cells/μL (IQR) | |
Overall | 239 (122–420) |
By sex | |
Male | 188 (89–345) |
Female | 273 (152–466) |
By route of HIV testing | |
CRH | 187 (85–382) |
HIV serosurvey | 277 (156–468) |
Missing | 240 (127–404) |
ART initiation
Factor | Unadjusted analysis | Adjusted analysis | ||||
---|---|---|---|---|---|---|
Hazard ratio | 95 % CI | p-value | Hazard ratio | 95 % CI | p-value | |
Sex
| 0.012 | 0.930 | ||||
Male | 1 (ref) | 1 (ref) | ||||
Female | 0.80 | 0.67–0.95 | 0.99 | 0.83–1.19 | ||
Age at enrolment
| 0.259 | 0.996 | ||||
15–34 | 1 (ref) | 1 (ref) | ||||
≥35 | 1.11 | 0.93–1.32 | 1.00 | 0.83–1.20 | ||
CD4 count (cells/μL) at enrolment
| <0.001 | <0.001 | ||||
≤250 | 1 (ref) | 1 (ref) | ||||
251–350 | 0.36 | 0.28–0.47 | 0.35 | 0.27–0.46 | ||
351–500 | 0.18 | 0.13–0.25 | 0.17 | 0.13–0.24 | ||
>500 | 0.12 | 0.09–0.16 | 0.12 | 0.09–0.17 | ||
Missing | 0.71 | 0.40–1.27 | 0.74 | 0.41–1.33 | ||
Year of enrolment
| 0.002 | <0.001 | ||||
2008 | 1 (ref) | 1 (ref) | ||||
2009 | 0.69 | 0.56–0.86 | 0.62 | 0.49–0.77 | ||
2010 | 0.89 | 0.71–1.11 | 0.74 | 0.59–0.93 | ||
2011 | 0.66 | 0.48–0.91 | 0.60 | 0.44–0.83 | ||
Route of HIV testing
| <0.001 | 0.009 | ||||
CRH | 1 (ref) | 1 (ref) | ||||
HIV serosurvey | 0.71 | 0.59–0.85 | 0.75 | 0.62–0.91 | ||
Missing | 1.04 | 0.77–1.41 | 1.01 | 0.74–1.38 |
Total—n | 432 |
---|---|
Registered within KHDSS—n (%)
| 398 (92) |
Route of HIV testing—n (%)
| |
CRH | 203 (47) |
HIV serosurvey | 181 (42) |
Missing | 48 (11) |
Sex—n (%)
| |
Male | 189 (44) |
Female | 243 (56) |
Age—n (%)
| |
15–34 | 162 (38) |
≥35 | 270 (63) |
Median age—years
| 38.0 |
Weight—kg
| |
Median (IQR) | 52.9 (46.8–58.4) |
Missing—n (%) | 12 (3) |
Median BMI
| 20.1 |
Year of ART initiation—n (%)
| |
2008 | 150 (35) |
2009 | 106 (25) |
2010 | 117 (27) |
2011 | 59 (14) |
WHO stage—n (%)
| |
1 | 49 (11) |
2 | 134 (31) |
3 | 203 (47) |
4 | 46 (11) |
CD4 count—n (%) cells/μL | |
≤250 | 285 (66) |
251–350 | 33 (8) |
351–500 | 14 (3) |
>500 | 9 (2) |
Missing | 91 (21) |
Median CD4 count—cells/μL (IQR)
| |
Overall | 156 (77–227) |
By route of HIV testing
| |
CRH | 139 (62–222) |
HIV serosurvey | 167 (108–227) |
Missing | 169 (69–244) |
Starting Regimen—n (%)
| |
d4T-3TC-NVPa
| 431 (99.8) |
TDF-3TC-EFVb
| 1 (0.2) |
Clinical Details—n (%)
| |
Weight loss >10 % | 107 (25) |
Oral candidiasis | 74 (17) |
Severe bacterial infection | 72 (17) |
Unexplained fever >1 month | 32 (7) |
Wasting syndrome | 14 (3) |
Pulmonary tuberculosis | 12 (3) |
Kaposi’s sarcoma | 10 (2) |
Oesophageal candidiasis | 9 (2) |
Extrapulmonary tuberculosis | 5 (1) |
Attrition on ART
Mortality on ART
Factor | Unadjusted analysis | Adjusted analysis | ||||
---|---|---|---|---|---|---|
Hazard ratio | 95 % CI | p-value | Hazard ratio | 95 % CI | p-value | |
Sex
| 0.016 | 0.040 | ||||
Male | 1 (ref) | 1 (ref) | ||||
Female | 0.57 | 0.36–0.90 | 0.61 | 0.38–0.98 | ||
Age
| 0.051 | 0.039 | ||||
15–34 | 1 (ref) | 1 (ref) | ||||
≥35 | 1.64 | 0.98–2.74 | 1.72 | 1.01–2.92 | ||
BMI
| 0.019 | 0.023 | ||||
≥18.5 | 1 (ref) | 1 (ref) | ||||
<18.5 | 1.82 | 1.12–2.95 | 1.65 | 1.00–2.72 | ||
Missing | 3.02 | 1.08–8.41 | 3.97 | 1.33–11.91 | ||
CD4 count (cells/μL)
| 0.021 | 0.010 | ||||
≤250 | 1 (ref) | 1 (ref) | ||||
>250 | 0.66 | 0.28–1.54 | 0.60 | 0.25–1.47 | ||
Missing | 1.87 | 1.13–3.10 | 2.09 | 1.19–3.69 | ||
WHO stage
| <0.001 | |||||
I & II | 1 (ref) | |||||
III & IV | 3.68 | 2.02–6.71 | ||||
Year of ART initiation
| 0.535 | 0.859 | ||||
2008 | 1 (ref) | 1 (ref) | ||||
2009 | 1.07 | 0.57–2.01 | 0.95 | 0.49–1.84 | ||
2010 | 1.48 | 0.81–2.68 | 1.25 | 0.67–2.31 | ||
2011 | 1.46 | 0.68–3.12 | 1.07 | 0.47–2.45 | ||
Route of HIV testing
| 0.010 | 0.004 | ||||
CRH | 1 (ref) | 1 (ref) | ||||
HIV serosurvey | 0.47 | 0.28–0.81 | 0.43 | 0.25–0.74 | ||
Missing | 1.07 | 0.55–2.07 | 1.07 | 0.54–2.10 |